
|Articles|December 1, 2004
Miravant selects new name for SnET2
Santa Barbara, CA-Miravant Medical Technologies has picked Photrex as the brand name for its tin ethyl etiopurpurin (SnET2) drug being developed for photodynamic therapy in the treatment of wet AMD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement

















